Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?

BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (ALL) cases. Previously, less than 40% of Philadelphia-positive ALL patients were cured with intensive chemotherapy. The use of imatinib (340 mg/m(2)/day) added to an intensive chemotherapy regimen has i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ay, Yilmaz, Yilmaz, Deniz, Balkan, Can, Karapinar, Bulent, Karadas, Nihal, Kavakli, Kaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: June 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130983/
https://www.ncbi.nlm.nih.gov/pubmed/21738503
http://dx.doi.org/10.1159/000330102
_version_ 1782207675360083968
author Ay, Yilmaz
Yilmaz, Deniz
Balkan, Can
Karapinar, Bulent
Karadas, Nihal
Kavakli, Kaan
author_facet Ay, Yilmaz
Yilmaz, Deniz
Balkan, Can
Karapinar, Bulent
Karadas, Nihal
Kavakli, Kaan
author_sort Ay, Yilmaz
collection PubMed
description BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (ALL) cases. Previously, less than 40% of Philadelphia-positive ALL patients were cured with intensive chemotherapy. The use of imatinib (340 mg/m(2)/day) added to an intensive chemotherapy regimen has improved the outcome in this population at 3 years to an event-free survival of 80%. Imatinib treatment alone was administered after remission induction chemotherapy to a patient with Philadelphia-positive ALL who presented with serious chemotherapy toxicity, so that intensive chemotherapy could not be maintained. This is the only patient in the literature who survived remission for more than 2.5 years with imatinib treatment only.
format Online
Article
Text
id pubmed-3130983
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-31309832011-07-07 Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough? Ay, Yilmaz Yilmaz, Deniz Balkan, Can Karapinar, Bulent Karadas, Nihal Kavakli, Kaan Case Rep Oncol Published: June 2011 BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (ALL) cases. Previously, less than 40% of Philadelphia-positive ALL patients were cured with intensive chemotherapy. The use of imatinib (340 mg/m(2)/day) added to an intensive chemotherapy regimen has improved the outcome in this population at 3 years to an event-free survival of 80%. Imatinib treatment alone was administered after remission induction chemotherapy to a patient with Philadelphia-positive ALL who presented with serious chemotherapy toxicity, so that intensive chemotherapy could not be maintained. This is the only patient in the literature who survived remission for more than 2.5 years with imatinib treatment only. S. Karger AG 2010-12-17 /pmc/articles/PMC3130983/ /pubmed/21738503 http://dx.doi.org/10.1159/000330102 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: June 2011
Ay, Yilmaz
Yilmaz, Deniz
Balkan, Can
Karapinar, Bulent
Karadas, Nihal
Kavakli, Kaan
Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title_full Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title_fullStr Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title_full_unstemmed Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title_short Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
title_sort imatinib treatment alone in philadelphia-positive acute lymphoblastic leukemia: is it enough?
topic Published: June 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130983/
https://www.ncbi.nlm.nih.gov/pubmed/21738503
http://dx.doi.org/10.1159/000330102
work_keys_str_mv AT ayyilmaz imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough
AT yilmazdeniz imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough
AT balkancan imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough
AT karapinarbulent imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough
AT karadasnihal imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough
AT kavaklikaan imatinibtreatmentaloneinphiladelphiapositiveacutelymphoblasticleukemiaisitenough

Ejemplares similares